Factor XIIa inhibitor Andembry (garadacimab) has been cleared in the US for use in patients aged 12 and over with HAE, which ...

Double-digit royalties on future net product sales3.5% equity stake in Intact Therapeutics HANOVER, Md., June 17, 2025 (GLOBE ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...

The specialty drug pipeline is robust with several new medications anticipated to gain approval in the coming years. Healthcare leaders need to be poised to have a deep understanding of the clinical ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular ...

A UroGen Pharma Ltd. investor has dropped his suit against the drug developer after the FDA approved the company’s new ...

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its 2025-26 budget plans.

Drug developer NextCure said on Monday it had signed a deal worth up to $745 million with China-based drugmaker Simcere Zaiming to develop a cancer therapy for solid tumors.

Stroke remains one of the leading causes of death, disability, increased economic burden and decreased quality of life around ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer ...